Diabetes Care, Vol 19, Issue 8 843-848, Copyright © 1996 by American Diabetes Association

ARTICLES

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

MK Gutniak, H Larsson, SJ Heiber, OT Juneskans, JJ Holst and B Ahren
Vallingby Medical Center, Stockholm, Sweden. mark.gutniak@mailbox.swipnet.se

OBJECTIVE: Glucagon-like peptide I(7-36) (GLP-I) amide, an endogenous incretin, has been identified as a potential adjunct to the treatment of NIDDM and has been studied following intravenous and subcutaneous injection. A mucoadhesive buccal GLP-I tablet containing 119 nmol has been developed to provide transmucosal absorption as a possible alternative to injection treatment. RESEARCH DESIGN AND METHODS: Eight healthy volunteers received a single tablet under fasting conditions in this randomized double-blind placebo-controlled study. A total GLP-I immunoreactivity was measured using COOH-terminal radioimmunoassay (RIA) (total peptide activity) and NH2-terminal RIA (active, nondegraded peptide). RESULTS: The mean (+/- SE) peak GLP-I concentration was 117 +/- 19 pmol/l and occurred 30 +/- 4 min after application. The mean placebo-adjusted area under curve was 8,145 +/- 873 pmol.min-1.l-1, consistent with a relative bioavailability of 7% versus intravenous injection and 47% versus subcutaneous injection. The levels of active peptide increased in parallel with total GLP-I. Half-life of peptide activity after buccal administration was 27 and 24 min measured with COOH-terminal and NH2-terminal RIA, respectively. Placebo adjusted insulin concentrations increased to a peak of 252 +/- 57 pmol/l, glucose decreased 1.4 +/- 0.2 mmo/l, and glucagon decreased 17 +/- 3 ng/l, consistent with the increase in plasma GLP-I concentrations. CONCLUSIONS: Therapeutic plasma levels of GLP-I in humans were achieved after a single buccal tablet. No increased degradation of GLP-I was found in the buccal mucosa compared to subcutaneous tissue. This alternative treatment form may be feasible in in the future for NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. D Green, N. Irwin, V. A Gault, F. P. O'Harte, and P. R Flatt Review: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 134 - 140. [Abstract] [PDF]

				S. V Joy, P. T Rodgers, and A. C Scates Incretin Mimetics as Emerging Treatments for Type 2 Diabetes Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118. [Abstract] [Full Text] [PDF]

				T. Nystrom, M. K. Gutniak, Q. Zhang, F. Zhang, J. J. Holst, B. Ahren, and A. Sjoholm Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1209 - E1215. [Abstract] [Full Text] [PDF]

				R. Ugleholdt, X. Zhu, C. F. Deacon, C. Orskov, D. F. Steiner, and J. J. Holst Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1 Endocrinology, March 1, 2004; 145(3): 1349 - 1355. [Abstract] [Full Text] [PDF]

				B. Ahren, J. J. Holst, and A. Mari Characterization of GLP-1 Effects on {beta}-Cell Function After Meal Ingestion in Humans Diabetes Care, October 1, 2003; 26(10): 2860 - 2864. [Abstract] [Full Text] [PDF]

				F. K. Knop, T. Vilsboll, S. Larsen, S. Madsbad, J. J. Holst, and T. Krarup No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis Diabetes Care, September 1, 2003; 26(9): 2581 - 2587. [Abstract] [Full Text] [PDF]

				T. Vilsboll, H. Agerso, T. Krarup, and J. J. Holst Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 220 - 224. [Abstract] [Full Text] [PDF]

				X. Zhu, A. Zhou, A. Dey, C. Norrbom, R. Carroll, C. Zhang, V. Laurent, I. Lindberg, R. Ugleholdt, J. J. Holst, et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects PNAS, August 6, 2002; 99(16): 10293 - 10298. [Abstract] [Full Text] [PDF]

				M.-B. Toft-Nielsen, S. Madsbad, and J. J. Holst Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3853 - 3860. [Abstract] [Full Text] [PDF]

				M. Zander, M. Taskiran, M.-B. Toft-Nielsen, S. Madsbad, and J. J. Holst Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 720 - 725. [Abstract] [Full Text]

				A. Vella, P. Shah, R. Basu, A. Basu, M. Camilleri, F. W. Schwenk, J. J. Holst, and R. A. Rizza Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes Diabetes, March 1, 2001; 50(3): 565 - 572. [Abstract] [Full Text]

				T. Vilsbøll, T. Krarup, C. F. Deacon, S. Madsbad, and J. J. Holst Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients Diabetes, March 1, 2001; 50(3): 609 - 613. [Abstract] [Full Text]

				K. Persson, R. L. Gingerich, S. Nayak, K. Wada, E. Wada, and B. Ahren Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice Am J Physiol Endocrinol Metab, November 1, 2000; 279(5): E956 - E962. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				B. Ahren and G. Pacini Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E996 - E1004. [Abstract] [Full Text] [PDF]

				L. Hansen, C. F. Deacon, C. Ørskov, and J. J. Holst Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine Endocrinology, November 1, 1999; 140(11): 5356 - 5363. [Abstract] [Full Text]

				E. Naslund, J. Bogefors, S. Skogar, P. Gryback, H. Jacobsson, J. J. Holst, and P. M. Hellstrom GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R910 - R916. [Abstract] [Full Text] [PDF]

				C.M.B. Edwards, M.A. Cohen, and S.R. Bloom Peptides as drugs QJM, January 1, 1999; 92(1): 1 - 4. [Full Text] [PDF]

				J-P Gutzwiller, B Goke, J Drewe, P Hildebrand, S Ketterer, D Handschin, R Winterhalder, D Conen, and C Beglinger Glucagon-like peptide-1: a potent regulator of food intake in humans Gut, January 1, 1999; 44(1): 81 - 86. [Abstract] [Full Text] [PDF]

				K. Filipsson, G. Pacini, A. J. W. Scheurink, and B. Ahren PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E834 - E842. [Abstract] [Full Text] [PDF]

				C. F. Deacon, A. Plamboeck, S. Moller, and J. J. Holst GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E873 - E879. [Abstract] [Full Text] [PDF]